Literature DB >> 26149714

Evolutionary consequences of drug resistance: shared principles across diverse targets and organisms.

Diarmaid Hughes1, Dan I Andersson1.   

Abstract

Drug therapy has a crucial role in the treatment of viral, bacterial, fungal and protozoan infections, as well as the control of human cancer. The success of therapy is being threatened by the increasing prevalence of resistance. We examine and compare mechanisms of drug resistance in these diverse biological systems (using HIV and Plasmodium falciparum as examples of viral and protozoan pathogens, respectively) and discuss how factors — such as mutation rates, fitness effects of resistance, epistasis and clonal interference — influence the evolutionary trajectories of drug-resistant clones. We describe commonalities and differences related to resistance development that could guide strategies to improve therapeutic effectiveness and the development of a new generation of drugs.

Entities:  

Mesh:

Year:  2015        PMID: 26149714     DOI: 10.1038/nrg3922

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  166 in total

Review 1.  Molecular mechanisms of antibacterial multidrug resistance.

Authors:  Michael N Alekshun; Stuart B Levy
Journal:  Cell       Date:  2007-03-23       Impact factor: 41.582

2.  Novel ribosomal mutations affecting translational accuracy, antibiotic resistance and virulence of Salmonella typhimurium.

Authors:  J Björkman; P Samuelsson; D I Andersson; D Hughes
Journal:  Mol Microbiol       Date:  1999-01       Impact factor: 3.501

3.  Evolution of the mutation rate.

Authors:  Michael Lynch
Journal:  Trends Genet       Date:  2010-06-30       Impact factor: 11.639

Review 4.  Towards an integrated model of bacterial conjugation.

Authors:  Elena Cabezón; Jorge Ripoll-Rozada; Alejandro Peña; Fernando de la Cruz; Ignacio Arechaga
Journal:  FEMS Microbiol Rev       Date:  2014-12-04       Impact factor: 16.408

Review 5.  Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.

Authors:  Mamta Sharma; Louis D Saravolatz
Journal:  J Antimicrob Chemother       Date:  2012-10-25       Impact factor: 5.790

6.  Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase.

Authors:  L M Mansky; H M Temin
Journal:  J Virol       Date:  1995-08       Impact factor: 5.103

Review 7.  HIV transmission.

Authors:  George M Shaw; Eric Hunter
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

8.  Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.

Authors:  Lisa M Demeter; Victor DeGruttola; Stephanie Lustgarten; Daniel Bettendorf; Margaret Fischl; Susan Eshleman; William Spreen; Bach-Yen Nguyen; Christine E Koval; Joseph J Eron; Scott Hammer; Kathleen Squires
Journal:  HIV Clin Trials       Date:  2008 Jan-Feb

9.  Dynamics of antibiotic resistant Mycobacterium tuberculosis during long-term infection and antibiotic treatment.

Authors:  Solomon H Mariam; Jim Werngren; Joakim Aronsson; Sven Hoffner; Dan I Andersson
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

10.  The genetic basis of the fitness costs of antimicrobial resistance: a meta-analysis approach.

Authors:  Tom Vogwill; R Craig MacLean
Journal:  Evol Appl       Date:  2014-12-12       Impact factor: 5.183

View more
  79 in total

1.  Within-Host Selection of Drug Resistance in a Mouse Model Reveals Dose-Dependent Selection of Atovaquone Resistance Mutations.

Authors:  Suci Nuralitha; Lydia S Murdiyarso; Josephine E Siregar; Din Syafruddin; Jessica Roelands; Jan Verhoef; Andy I M Hoepelman; Sangkot Marzuki
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

2.  Soft sweep development of resistance in Escherichia coli under fluoroquinolone stress.

Authors:  Xianxing Xie; Ruichen Lv; Chao Yang; Yajun Song; Yanfeng Yan; Yujun Cui; Ruifu Yang
Journal:  J Microbiol       Date:  2019-09-25       Impact factor: 3.422

3.  Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations.

Authors:  Petra Szili; Gábor Draskovits; Tamás Révész; Ferenc Bogár; Dávid Balogh; Tamás Martinek; Lejla Daruka; Réka Spohn; Bálint Márk Vásárhelyi; Márton Czikkely; Bálint Kintses; Gábor Grézal; Györgyi Ferenc; Csaba Pál; Ákos Nyerges
Journal:  Antimicrob Agents Chemother       Date:  2019-08-23       Impact factor: 5.191

Review 4.  New facets of antifungal therapy.

Authors:  Ya-Lin Chang; Shang-Jie Yu; Joseph Heitman; Melanie Wellington; Ying-Lien Chen
Journal:  Virulence       Date:  2016-11-07       Impact factor: 5.882

Review 5.  Prediction of antibiotic resistance: time for a new preclinical paradigm?

Authors:  Morten O A Sommer; Christian Munck; Rasmus Vendler Toft-Kehler; Dan I Andersson
Journal:  Nat Rev Microbiol       Date:  2017-07-31       Impact factor: 60.633

Review 6.  Evolutionary scalpels for dissecting tumor ecosystems.

Authors:  Daniel I S Rosenbloom; Pablo G Camara; Tim Chu; Raul Rabadan
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2016-12-05       Impact factor: 10.680

7.  Adaptation Through Lifestyle Switching Sculpts the Fitness Landscape of Evolving Populations: Implications for the Selection of Drug-Resistant Bacteria at Low Drug Pressures.

Authors:  Nishad Matange; Sushmitha Hegde; Swapnil Bodkhe
Journal:  Genetics       Date:  2019-01-22       Impact factor: 4.562

8.  Catabolism of aromatic β-glucosides by bacteria can lead to antibiotics resistance.

Authors:  Kartika Vashishtha; S Mahadevan
Journal:  Arch Microbiol       Date:  2020-03-04       Impact factor: 2.552

Review 9.  Evolving lessons on nanomaterial-coated viral vectors for local and systemic gene therapy.

Authors:  Dayananda Kasala; A-Rum Yoon; Jinwoo Hong; Sung Wan Kim; Chae-Ok Yun
Journal:  Nanomedicine (Lond)       Date:  2016-06-27       Impact factor: 5.307

10.  Anti-infective Activity of 2-Cyano-3-Acrylamide Inhibitors with Improved Drug-Like Properties against Two Intracellular Pathogens.

Authors:  Karla D Passalacqua; Marie-Eve Charbonneau; Nicholas J Donato; Hollis D Showalter; Duxin Sun; Bo Wen; Miao He; Hanshi Sun; Mary X D O'Riordan; Christiane E Wobus
Journal:  Antimicrob Agents Chemother       Date:  2016-06-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.